Abstract:Purpose: Molecular biomarkers informing disease diagnosis, prognosis, and treatment decisions in patients with breast cancer are being uncovered by next-generation sequencing (NGS) technologies. In this study, we survey how NGS is used for patients with breast cancer in real-world settings with a focus on physician behaviors and sequencing results. Methods: We conducted a retrospective analysis of patients with breast cancer who received NGS testing from commercial vendors as part of standard of care from 2014 to 2019. A total of 2,635 NGS reports from 2,316 unique breast cancer patients were assessed. Hormone receptor and human epidermal growth factor receptor 2 statuses were abstracted from patient medical records. Comparative gene amplification and mutation frequencies were analyzed using Pearson's correlation and Lin's concordance statistics. Results: The number of physicians ordering NGS tests for patients with breast cancer increased more than six-fold from 2014 to 2019. Tissue- and plasma-based tests were ordered roughly equally by 2019, with plasma-based testing ordered most frequently in hormone receptor-positive subtypes. Patients with triple-negative breast cancer were most likely to receive NGS testing. Gene amplifications including ERBB2 were detected less frequently in our real-world data set as compared to previous genomic landscape studies, whereas the opposite was true for gene mutations including ESR1. Pathogenic mutations in the PI3K pathway (38.6%) and DNA damage repair pathway (11.0%) were frequently reported. Alterations were also reported across other cellular pathways. Conclusion: Overall, we found that an increasing number of physicians in community settings are adopting NGS in the care of patients with breast cancer. Discrepancies between our real-world NGS data and previous genomic landscape studies are likely owed to the prevalence of plasma-based testing in community oncology clinics, as the reference data were from tissue-based NGS alone.

Cancer treatment comes to age: from one-size-fits-all to next-generation sequencing (NGS) technologies

CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer

Revolutionizing personalized cancer treatment: the synergy of next-generation sequencing and CRISPR/Cas9

Clinical Next Generation Sequencing for Precision Medicine in Cancer

Advances in Personalized Oncology

The Development of Cancer Genome Research and Its Clinical Opportunity Brought by Next Generation Sequencing

Cancer modelling in the NGS era - Part I: Emerging technology and initial modelling

Next-generation sequencing impact on cancer care: applications, challenges, and future directions

Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?

Navigating the Rapids: The Development of Regulated Next-Generation Sequencing-Based Clinical Trial Assays and Companion Diagnostics

Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine

Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review

Next-Generation Sequencing Trends among Adult Patients with Select Advanced Tumor Types: A Real-World Evidence Evaluation

Application of next-generation sequencing in the diagnosis of gastric cancer

Next-generation sequencing in the clinic: Promises and challenges

Application of Genomic Technology in Early Diagnosis and Personalized Treatment for Cancer Patients

Next Generation Sequencing in Oncological Diagnostics: Hype or Hope?

Computational methods and translational applications for targeted next‐generation sequencing platforms

Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics

Next Generation Sequencing Technology in the Clinic and Its Challenges

The Application of Long-Read Sequencing to Cancer